Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2287]

Addressing the treatment gap for patients with relapsed/refractory primary...

Prof Evangelos Terpos and Prof Efstathios Kastritis

$Addressing the treatment gap for patients with relapsed/refractory primary systemic AL amyloidosis: TOURMALINE-AL1 trial results ( Prof Evangelos Terpos and Prof Efstathios Kastritis )$

Challenges and importance of long-term treatment for newly diagnosed multiple...

Prof Sagar Lonial, Prof Meral Beksaç, Dr Robert Rifkin

Challenges and importance of long-term treatment for newly diagnosed multiple myeloma patients; community-based trial data ( Prof Sagar Lonial, Prof Meral Beksaç, Dr Robert Rifkin )

Evaluating emerging mutations in patients with acute myeloid leukaemia who...

Dr Catherine Smith - University of California San Francisco, San Francisco, USA

Evaluating emerging mutations in patients with acute myeloid leukaemia who relapsed while receiving gilteritinib therapy in the ADMIRAL trial ( Dr Catherine Smith - University of California San Francisco, San Francisco, USA )

Bispecific CAR T-cell therapy as treatment for hard to treat multiple myeloma

Dr Yu Hu - Huazhong University of Science and Technology, Wuhan, China

Bispecific CAR T-cell therapy as treatment for hard to treat multiple myeloma ( Dr Yu Hu - Huazhong University of Science and Technology, Wuhan, China )

CAR T-cell therapy in hard-to-treat multiple myeloma produces sustained...

Dr Yu Hu - Huazhong University of Science and Technology, Wuhan, China

CAR T-cell therapy in hard-to-treat multiple myeloma produces sustained remissions ( Dr Yu Hu - Huazhong University of Science and Technology, Wuhan, China )

Dual-targeted antibody mosunetuzumab elicits durable responses in poor...

Prof Stephen Schuster - University of Pennsylvania, Philadelphia, USA

Dual-targeted antibody mosunetuzumab elicits durable responses in poor-prognosis non-Hodgkin Lymphoma patients ( Prof Stephen Schuster - University of Pennsylvania, Philadelphia, USA )

JCOG: The Japan Clinical Oncology Group

Dr Tomonori Mizutani - Kyorin University, Mitaka, Tokyo

JCOG: The Japan Clinical Oncology Group ( Dr Tomonori Mizutani - Kyorin University, Mitaka, Tokyo )

Immunotherapy and targeted agents for elderly lung cancer patients

Dr Lore Decoster - University Hospital Brussels, Brussels, Belgium

Immunotherapy and targeted agents for elderly lung cancer patients ( Dr Lore Decoster - University Hospital Brussels, Brussels, Belgium )

Treatment pathways for patients with triple-negative breast cancer

Elahe Salehi - Dana-Farber Cancer Institute, Boston, USA

Treatment pathways for patients with triple-negative breast cancer ( Elahe Salehi - Dana-Farber Cancer Institute, Boston, USA )

PARP inhibitors in metastatic breast cancer: The present and the future

Elahe Salehi - Dana-Farber Cancer Institute, Boston, USA

PARP inhibitors in metastatic breast cancer: The present and the future ( Elahe Salehi - Dana-Farber Cancer Institute, Boston, USA )

The challenge of detecting NTRK fusions across tumour types

Professor Dr Marc Peeters, Professor Caterina Marchio

The challenge of detecting NTRK fusions across tumour types ( Professor Dr Marc Peeters, Professor Caterina Marchio )

The latest research highlights in lymphoma

Corinne Williams, PA-C, President of APAO

The latest research highlights in lymphoma ( Corinne Williams, PA-C, President of APAO )

More from ecancer